Spark Therapeutics price target raised to $78 from $64 at BMO Capital. BMO Capital analyst Matthew Luchini raised his price target on Spark Therapeutics to $78 and kept his Outperform rating after its Q1 results. The analyst notes that the company’s Luxturna sales, as well as progress in payer agreements and approvals, are encouraging, adding that patient identification will be key in maximizing the program’s opportunity. Luchini also cites continued investor focus on SPK-8011 for HemA, where data are expected in Q3
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.